EpiSwitch PSE
Blood-based 3D-genomics test used with PSA to assess current likelihood of prostate cancer.
- Developer
- Oxford BioDynamics
- Intended use
- Diagnostic Aid
- Cancer scope
- Prostate cancer
- Specimen
- Whole blood
- Molecular modality
- DNA
- Current version
- Current EpiSwitch PSE configuration (2026-09)
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.